Insulin biosimilars are biologic products that are highly similar to approved reference insulin products. They offer a cost-effective alternative to brand-name insulin while maintaining comparable safety, efficacy, and quality. By increasing competition in the market, insulin biosimilars hold the potential to drive down costs and improve affordability, thereby enhancing patient access to life-saving diabetes treatments. […]
